NCT03928821View on ClinicalTrials.gov

Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 17, 2019

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions
HIV Infections
Interventions
BIOLOGICAL

PGT121

20 mg/kg administered intravenously

BIOLOGICAL

PGDM1400

20 mg/kg administered intravenously

BIOLOGICAL

10-1074

20 mg/kg administered intravenously

BIOLOGICAL

VRC07-523LS

20 mg/kg administered intravenously

Trial Locations (4)

10027

Harlem Prevention Center CRS, New York

02215-4302

Fenway Health (FH) CRS, Boston

10032-3732

Columbia P&S CRS, New York

37232-2582

Vanderbilt Vaccine (VV) CRS, Nashville

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03928821 - Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants | Biotech Hunter | Biotech Hunter